MONTREAL, Canada, May 29, 2026
Leica Biosystems, a global leader in anatomic and digital pathology solutions, and CellCarta, a leading precision medicine laboratory services provider, have announced the expansion of their successful companion diagnostic (CDx) development collaboration beyond China to global biopharmaceutical markets. The strategic partnership introduces a flexible framework designed to accelerate companion diagnostic development, regulatory approval, and commercialization, helping pharmaceutical companies bring precision medicine solutions to patients more efficiently. The initiative combines diagnostic innovation, digital pathology expertise, and streamlined development strategies to support the growing demand for personalized healthcare solutions.
Global CDx Framework Designed to Accelerate Precision Medicine
The expanded collaboration leverages a proven development model established in China and adapts it for international markets. The framework is designed to integrate assay development, clinical trial execution, regulatory planning, and commercial diagnostic kit development within a unified process. By enabling parallel progression of these activities, the model allows biopharma sponsors to reduce development complexity while maintaining clinical timelines and adapting to evolving regulatory requirements.
A major advantage of the framework is its ability to help organizations avoid duplication of work during diagnostic development while creating a more efficient path toward registration and commercialization. The model also incorporates CellCarta’s innovative CDx Bridge Model, which combines the speed of centralized testing with the scalability of a global laboratory network. This approach supports faster market readiness while reducing risks associated with complex precision medicine programs. The collaboration aims to provide pharmaceutical developers with greater flexibility, improved efficiency, and a clearer pathway to bringing diagnostic-driven therapies to patients worldwide.
Digital Pathology and AI Strengthen Diagnostic Development
Advertisement
A key differentiator of the partnership is the integration of advanced digital pathology and artificial intelligence technologies into the companion diagnostic workflow. Leica Biosystems contributes its industry-leading pathology solutions, including Aperio digital scanners, HALO image analysis platforms, HALO Dx solutions, and an expanding AI-enabled ecosystem. Combined with CellCarta’s expertise in deploying globally standardized digital pathology platforms for clinical studies, the collaboration creates a robust infrastructure for next-generation diagnostic development.
The integrated platform is designed to enable standardized pathology workflows, scalable image analysis across multiple regions, and consistent implementation of computational pathology in both clinical research and commercial diagnostic settings. By embedding digital pathology directly into companion diagnostic development, the partners aim to improve assay performance, enhance data consistency, and support the broader adoption of data-driven precision medicine. These capabilities are increasingly important as healthcare systems move toward personalized treatment strategies supported by advanced diagnostic technologies.
Supporting Faster Commercialization of Companion Diagnostics
Industry leaders from both organizations emphasized that the expanded collaboration addresses growing demand for faster, more flexible, and cost-efficient companion diagnostic development. By aligning clinical trial assays with future commercial kit strategies from the earliest stages of development, the model helps preserve timelines, reduce rework, and create a smoother transition from research to commercial availability.
As precision medicine continues to transform oncology and other therapeutic areas, companion diagnostics play an increasingly critical role in identifying the right patients for targeted therapies. The global expansion of this collaborative model positions Leica Biosystems and CellCarta to support biopharmaceutical companies seeking efficient pathways to diagnostic commercialization while maintaining quality, regulatory compliance, and scientific rigor. The partnership represents a significant advancement in the evolution of precision medicine infrastructure and highlights the growing importance of digital pathology, AI-powered diagnostics, and companion diagnostic innovation in modern healthcare.
Source: Leica Biosystems, CellCarta press release
